Epilepsy in patients with MOG antibody disease


如何引用文章

全文:

详细

Introduction. MOG (anti-myelin oligodendrocyte glycoprotein) antibody disease is a group of demyelinating disorders of the central nervous system, in which antibodies attack the glycoproteins on the oligodendrocyte myelin membrane. The aim of the study was to evaluate the course of the disease in patients with MOG antibody disease with epilepsy.

Materials and methods. We examined 11 patients (5 men and 6 women) with MOG antibody disease aged from 2 months to 46 years. Three case studies were described when patients with MOG antibody disease had epileptic seizures.

Results and discussion. Epileptic seizures preceded the diagnosis of MOG antibody disease in the first patient. The disease presented as right-sided optic neuritis in the second patient. Seven years later, an epileptic seizure occurred after childbirth, when the BBB could have become permeable to circulating MOG antibodies. The disease presented with headache in the third patient. Right-sided optic neuritis and ataxia developed after an acute viral respiratory infection. Myelitis was diagnosed, and an epileptic seizure occurred one year later. The patient had a combination of CADASIL syndrome with MOG antibody disease.

Conclusion. Epileptic seizures are common in patients with MOG antibody disease. In addition to antiepileptic therapy, treatment of MOG antibody disease is crucial. This leads to good seizure control and a favourable prognosis.

作者简介

Varvara Avdeeva

M.F. Vladimirsky Moscow Regional Research and Clinical Institute; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

编辑信件的主要联系方式.
Email: varvara-kitaeva@mail.ru
ORCID iD: 0000-0002-9334-8246

senior laboratory assistant, Department of neurology in the Science section; student, Medical faculty,

俄罗斯联邦, 129110, Russia, Moscow, Shchepkina str., 61/2; Moscow

Aleksey Kotov

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Email: alexeykotov1980@gmail.com
ORCID iD: 0000-0003-2988-5706

D. Sci. (Med.), Head, Neurological department in the Science section, Professor, Department of neurology

俄罗斯联邦, 129110, Russia, Moscow, Shchepkina str., 61/2

参考

  1. Jurynczyk M., Messina S., Woodhall M.R. et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140: 3128–3138. doi: 10.1093/brain/awx276. PMID: 29136091.
  2. Kotov A.S. Anti-MOG syndrome: two case reports. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2019; 11: 84–88. doi: 10.14412/2074-2711-2019-1-84-88. (In Russ.)
  3. Yamamoto Y., Craggs L.J.L., Watanabe A. et al. Brain microvascular accumulation and distribution of the NOTCH3 ectodomain and granular osmiophilic material in CA-DASIL. J Neuropathol Exp Neurol. 2013; 72: 416–431. doi: 10.1097/NEN.0b013e31829020b5. PMID: 23584202.
  4. Paraskevas G.P., Bougea A., Synetou M. et al. CADASIL and autoimmunity: coexistence ina family with the R169C mutation at exon 4 of the NOTCH3 gene. Cerebrovasc Dis. 2014; 38: 302–307. doi: 10.1159/000369000. PMID: 25412914.
  5. Fovet C.M., Stimmer L., Contreras V. et al. Intradermal vaccination prevents anti-MOG autoimmune encepha-lomyelitis inmacaques. EBioMedicine. 2019; 47: 492–505. doi: 10.1016/j.ebiom.2019.08.052. PMID: 31492559.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Avdeeva V.E., Kotov A.S., 2021

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##